ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Budesonide

Also written as “budesonide”, “budesonide/formoterol” and “BGF MDI 320/14.4/9.6 μg”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Eosinophilic Esophagitis · Colitis, Ulcerative · Glomerulonephritis, IGA, led by 35 companies.

Drug pageBudesonide: every studyMany companies study it; this page follows only the 163 they lead. All 307 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 27, 2005163 company-led studies, 8 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca692 open or runningphase 4since Sep 27, 2005Sep 13, 2005May 31, 2027phase 4 · NCT07073950
Dr. Falk Pharmaits history only171 open or runningphase 3since Mar 7, 2006Mar 7, 2006Dec 2026phase 3 · NCT06596252
Bausch Health Companiesits history only91 open or runningphase 4since Mar 17, 2020May 14, 2008Dec 2026phase 4 · NCT04314375
Takedaits history only60 open or runningphase 3since Nov 4, 2015Sep 29, 2008none ahead
AbbVieits history only50 open or runningphase 3since Dec 5, 2007Oct 30, 2007none ahead
Calliditas Therapeutics ABits history only51 open or runningphase 4since Nov 20, 2024Oct 5, 2008Mar 2027phase 4 · NCT06712407
Intech Biopharmits history only50 open or runningphase 2since Jun 11, 2014Jun 11, 2014none ahead
Chenpon Pharmaceuticalits history only30 open or runningphase 3since Aug 24, 2026Aug 24, 2026none ahead
Eurofarma Laboratoriosits history only30 open or runningphase 3since Oct 23, 2009Oct 23, 2009none ahead
Novartisits history only30 open or runningphase 4since Feb 15, 2013Feb 15, 2013none ahead

Also a collaborator on its studies: Parexel, Fortrea, Takeda Development Center Americas, Iqvia Pty, Premier, Hikma Pharmaceuticals, Cosmo Technologies, MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan, Q-Pharm Pty and Kyowa Kirin.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Nov 11, 2005.

  1. Feb 17, 2016Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT03262012 · 416 enrolled · Japan
  2. May 6, 2016Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT02766608 · 2,389 enrolled · United States, Canada, Czechia and more
  3. Sep 24, 2018Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT03836677 · 23 enrolled · Belgium, Netherlands
  4. Oct 26, 20202 phase 3 studies in AsthmaNCT04609904, NCT04609878
  5. Jan 10, 2022Phase 3 study in AsthmaNCT05202262 · 645 enrolled · United States, Canada, Germany and more
  6. Feb 23, 2023Phase 3 study in AsthmaNCT05755906 · 374 enrolled · United States, Canada, Czechia and more
  7. Jun 27, 2023Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT05970263
  8. Sep 28, 2023Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT06067828 · 171 enrolled · United States, Canada, China and more
  9. Dec 13, 2023Phase 3 study in Asthma, Exercise-InducedNCT06245551 · 64 enrolled · Russia
  10. Feb 21, 2024Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT06283966 · 5,250 planned · United States, Argentina, Australia and more
  11. May 29, 2024Phase 1 study in Healthy VolunteerNCT06514157 · 14 enrolled · China
  12. Aug 19, 2024Phase 4 study in Respiratory HypersensitivityNCT06563102 · 101 enrolled · United States
  13. Jul 17, 2025Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT07073950 · 56 planned · Germany, United Kingdom
  14. Feb 20, 2026Phase 1 study in AsthmaNCT07433569 · 16 enrolled · United States

Ahead

  1. May 31, 2027Primary completion: phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT07073950
  2. Dec 3, 2027Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT06283966

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
BetamethasoneruleLEO Pharmaphase 49
Triamcinoloneruleresearch-insight-llcphase 45
relacorilantruleCorcept Therapeuticsphase 322
Triamcinolone Acetonideruleclearside-biomedical-incphase 320

Studies

The newest 60 of 69 AstraZeneca leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT07433569Asthma · United States1CompletedJun 26, 202616
NCT07073950Pulmonary Disease, Chronic Obstructive · Germany, United Kingdom4RecruitingMay 31, 202756
NCT06563102Respiratory Hypersensitivity · United States4CompletedFeb 24, 2026101
NCT06514157Healthy Volunteer · China1CompletedSep 9, 202414
NCT06283966Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more3RecruitingDec 3, 20275,250
NCT06245551Asthma, Exercise-Induced · Russia3CompletedJun 29, 202464
NCT06067828Pulmonary Disease, Chronic Obstructive · United States, Canada, China and more3CompletedJan 22, 2026171
NCT05970263Pulmonary Disease, Chronic Obstructive4WithdrawnDec 31, 20250
NCT05755906Asthma · United States, Canada, Czechia and more3CompletedNov 19, 2024374
NCT05202262Asthma · United States, Canada, Germany and more3CompletedFeb 26, 2025645
NCT04609904Asthma · United States, Brazil, China and more3CompletedMar 20, 20252,187
NCT04609878Asthma · United States, Argentina, Belgium and more3CompletedMar 21, 20252,274
NCT03836677Pulmonary Disease, Chronic Obstructive · Belgium, Netherlands3CompletedNov 11, 201923
NCT02766608Pulmonary Disease, Chronic Obstructive · United States, Canada, Czechia and more3CompletedDec 1, 20172,389
NCT03262012Pulmonary Disease, Chronic Obstructive · Japan3CompletedJun 15, 2018416
NCT02536508Pulmonary Disease, Chronic Obstructive · United States3CompletedSep 12, 2017627
NCT02533505Pulmonary Disease, Chronic Obstructive · United States4CompletedAug 12, 201651
NCT02497001Pulmonary Disease, Chronic Obstructive · United States, Canada, China and more3CompletedJan 5, 20181,902
NCT02465567Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more3CompletedJul 26, 20198,588
NCT02196077Pulmonary Disease, Chronic Obstructive · United States2CompletedMar 1, 2015180
NCT02189304Pulmonary Disease, Chronic Obstructive · United States1CompletedSep 1, 201459
NCT01360021Asthma · United States, Bulgaria, Hungary and more3CompletedAug 2012214
NCT01257048Pulmonary Disease, Chronic Obstructive · Sweden, United KingdomEarly 1CompletedJun 201234
NCT01136382Asthma · United States, Bulgaria, Hungary and more2CompletedApr 2013304
NCT00989833Asthma, Exercise-Induced · Norway, Sweden2CompletedJul 201066
NCT00855959Asthma · Japan3CompletedAug 2009108
NCT00658255Stable Asthma2Completed175
NCT00652392Asthma3Completed750
NCT00652002Asthma3Completed450
NCT00651768Asthma3Completed570
NCT00651651Asthma3Completed450
NCT00651547Asthma3Completed405
NCT00646009Asthma3Completed48
NCT00642187Asthma3CompletedOct 2004525
NCT00642161Asthma3CompletedSep 2004430
NCT00642122Asthma3CompletedDec 2004900
NCT00641979Rhinitis, Allergic, Seasonal2CompletedAug 2002200
NCT00641914Asthma4CompletedFeb 20036,800
NCT00641693Rhinitis, Allergic2CompletedMay 2005650
NCT00641680Rhinitis, Allergic, Seasonal3CompletedJul 2003750
NCT00641472Asthma4CompletedFeb 2005380
NCT00641446Asthma4CompletedOct 2003250
NCT00641212Rhinitis, Allergic, Perennial4CompletedApr 2003209
NCT00536731Asthma · Bulgaria, Czech Republic, Hungary and more3CompletedApr 2008742
NCT00536913Asthma · Hungary, Poland, Russian Federation3CompletedFeb 2008107
NCT00509028Asthma · Japan3CompletedOct 2008241
NCT00504062Asthma · Japan3Completed240
NCT00489853Pulmonary Disease, Chronic Obstructive · Germany, Switzerland4CompletedAug 2008137
NCT00463866Asthma · Belgium, Finland, France and more4Completed8,424
NCT00421122Pulmonary Disease, Chronic Obstructive · China3Completed315
NCT00326053Asthma · Canada3Completed600
NCT00319306Asthma · United Kingdom3Completed550
NCT00290264Asthma · Belgium, Luxembourg3Completed1,000
NCT00288379Asthma · Sweden3Completed16
NCT00272753Asthma · Netherlands4Completed20
NCT00259792Asthma · France3Completed1,000
NCT00259779Pulmonary Disease, Chronic Obstructive · Denmark, Finland, Germany and more3Completed120
NCT00259766Asthma · Sweden3Completed1,970
NCT00255255Asthma · Japan3CompletedDec 2006120
NCT00252785Asthma · Japan3Completed340

How it is read

Names in the registry

  • “Budesonide”, 45 entries
  • “budesonide”, 18 entries
  • “budesonide/formoterol”, 10 entries
  • “BGF MDI 320/14.4/9.6 μg”, 6 entries
  • “BFF MDI 320/9.6 μg”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.